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Previously thought to be a pure motor disease, amyotrophic lateral sclerosis (ALS) is now
established as multisystem neurodegenerative disorder that lies on a continuum with
frontotemporal dementia (FTD). Cognitive and behavioral symptoms primarily extend to
executive function, personality, social conduct, and emotion processing. The assessment
and management of cognitive and behavioral symptoms is complicated as they must
be differentiated from psychological responses to a terminal diagnosis and progressive
physical impairment. This is made more difficult by the limited number of studies
investigating how these symptoms specifically affect patients and caregivers well-being.
The current review focuses on the impact of cognitive and behavioral symptoms
on patient and caregiver well-being and their implications for future research and
interventions in ALS. This is an important area of research that could form the basis
for more tailored, and potentially more successful, non-pharmacological interventions to
improve psychological well-being among patients with ALS and their caregivers.
Keywords: amyotrophic lateral sclerosis, dementia, depression, quality of life, caregiver, burden, adherence,
non-pharmacological interventions
BACKGROUND
Amyotrophic lateral sclerosis (ALS) is a multisystem neurodegenerative disorder which includes
a broad spectrum of non-motor symptoms that can dominate the clinical presentation (1, 2).
Cognitive and behavioral symptoms include impaired executive function, deficits in social and
emotional cognition, apathy, disinhibition, and perseveration similar to that seen in frontotemporal
dementia (FTD). Frontotemporal dysfunction of varying severity can affect more than 50% of
ALS patients (3), with ∼8–14% meeting full diagnostic criteria for FTD (4–8). As such, early
detection and timely management of cognitive and behavioral symptoms is widely acknowledged
as an important aspect of contemporary ALS care (9). However, fully assessing cognitive and
behavioral symptoms in ALS ismade difficult by the fact that these symptomsmust be distinguished
from psychological reactions to a terminal diagnosis and the progressive physical loss that
comes alongside it. Our narrative review focuses on evaluating the impact of cognitive and
behavioral symptoms on patient and caregiver well-being and their implications for developing
future non-pharmacological interventions in ALS. Gathering this research can help form more
appropriate and effective non-pharmacological interventions to improve psychological well-being
among patients with ALS and their caregivers.
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SEARCH STRATEGY AND SELECTION
CRITERIA
For this narrative review references were primarily searched
through PubMed. The following terms were systematically
searched: “amyotrophic lateral sclerosis”; “motor neuron(e)
disease”; “cognitive”; “behavioral”; “depression”; “anxiety”;
“quality of life”; “psychological health”; “caregiver”; “carer”;
“burden”; “strain”; “stress”; “compliance”; “adherence”;
“psychosocial intervention”; “non-pharmacological
intervention”; “support”; “manage”; “intervention”; “care”;
“caring”; “coping”; “cope”; “frontotemporal dementia.” The
section on non-pharmacological interventions for cognitive and
behavioral symptoms in ALS also used the MEDLINE, EMBASE,
PsycINFO, AMED, and CINAHL databases. Searches included
papers published in English between May/2013 and July/2018.
Research articles relevant to ALS and FTD were included in
the review.
PSYCHOLOGICAL SYMPTOMS IN ALS
The psychological impact of ALS has been widely addressed in
the literature. Anxiety and depression, particularly depression
are often used as clinical markers of psychological morbidity in
patients diagnosed with ALS. Self-report measures, particularly
the Hospital Anxiety and Depression Scale and Beck’s Depression
Inventory remain the most widely used measures. Based on the
Structured Clinical Interview for the Diagnostic and Statistical
Manual of Mental Disorders, the “gold standard” for assessment
of depression, the rate of clinical depression ranges between
9 and 12% in ALS (10, 11). Perhaps not surprisingly, self-
report measures of depression tend to show more variable rates
of depression ranging from 20 to 64% (12–20). Similarly, the
prevalence rates of anxiety vary widely, with rates ranging as low
as 8% to as high as 88% among patients with ALS (12, 14, 18,
19, 21). The severity of symptoms appear to be predominantly
in the mild range. Despite the low rates of clinical depression and
anxiety, patients with ALS have been shown to be at increased risk
of being diagnosed with depression, anxiety and other neurotic or
stress-related disorders following diagnosis (21–25), however this
may be attributable to the clinicopathological overlap between
ALS and FTD (24).
Management of psychological symptoms is crucial to
maintaining quality of life. ALS patients provided with an
assistive communication device in the early stages of the disease
have been found to experience higher quality of life, particularly
in the domains related to psychological and existential well-
being (26). Quality of life and depression appear to be largely
unrelated to patients’ desire for hastened death (27) and end-
of-life choices (28). This may be due to satisfactory levels of
quality of life typically reported by ALS patients (29, 30). In
fact, several studies have shown that caregivers and healthy
controls tend to underestimate ALS patients quality of life and
psychological well-being (31), possibly reflecting a “disability
paradox” (32). However, it should be noted that many quality of
life measurements used were not ALS specific.
THE IMPACT OF COGNITIVE AND
BEHAVIORAL SYMPTOMS ON ALS
PATIENT’S PSYCHOLOGICAL
WELL-BEING
To date, there is a paucity of research specifically examining
cognitive/behavioral symptoms and patients’ psychological
well-being. The majority of recent studies on patients’
psychological well-being have either excluded patients with
cognitive/behavioral symptoms or have not specifically discussed
findings in relation to cognitive/behavioral symptoms. This
is an important area for future research given emerging
findings showing a relationship between depression and
cognitive/behavioral changes. Higher levels of depression
have been associated with lower cognitive performance on
the Edinburgh Cognitive and Behavioral ALS Screen (17),
specifically the subtests measuring social cognitive deficits
and inhibitory control (12). Findings regarding anxiety and
cognitive function are inconsistent, with one recent study finding
no relationship (12) and another showing a weak association
between anxiety and cognitive performance, perhaps reflecting
underlying behavioral changes, namely disinhibition (17).
Indeed, the findings available on behavioral and psychological
symptoms appear to be more consistent. A large scale study of
cognitive and behavioral impairment, and depression showed
that patients with behavioral impairment exhibited higher levels
of depression and hopelessness (10). This may partly reflect the
overlap between depression and behavioral symptoms, namely
apathy (33, 34).
THE IMPACT OF COGNITIVE AND
BEHAVIORAL SYMPTOMS ON
TREATMENT ADHERENCE IN ALS
Adherence to treatment recommendations in ALS can extend
survival (e.g., non-invasive ventilation or Riluzole), improve
patients’ quality of life (35, 36), and likely to reduce caregiver
burden. Review articles of cognition and behavioral symptoms
in ALS discuss the likely impact of these symptoms on
treatment adherence (37–40), however only one study to date
has investigated the effect of non-motor symptoms on treatment
adherence in ALS (41). Non-adherence to non-invasive positive-
pressure ventilation and percutaneous endoscopic gastrostomy
recommendations was 75 and 72% respectively for patients
with ALS-FTD compared to 38 and 31% those with “motor
only” symptoms. Therefore, the presence of a frontotemporal
syndrome reduced adherence by half in ALS.
In general, ALS patients are compliant with recommendations
made in multidisciplinary clinics (36). Out of a total of 287
recommendations made to 25 patients with ALS, patients
complied fully with 59% of the recommendations made by
the team. Not surprisingly, recommendations were greatest
for physical needs (e.g., medications for symptoms such as
spasm, saliva, sleep difficulties and interventions for nutrition
and speech) and adherence was also highest for this category
of recommendations. Interestingly, while patients with marked
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cognitive impairment were excluded in this study, patients
with milder cognitive and behavioral symptoms (e.g., executive
dysfunction) were included and may help explain why less than
half of all recommendations were recalled (40%) and only a small
proportion of patients (32%) had retained the written list of
recommendations provided after the clinic visit. In total, <5%
of the total recommendations were for mental health needs of
patients (e.g., anti-depressants) and almost no recommendations
(<2% of total recommendations) were made for caregivers (e.g.,
increase caregiver hours, ALS respite care program, and caregiver
training to aid in patient transport).
In general, studies of treatment adherence in ALS have not
typically characterized non-motor symptoms in patient cohorts
[e.g., physiotherapy exercises (42); respiratory support (43);
tolerability of oral vs. tablet Riluzole (44); tolerability of early
non-invasive ventilation use (45)] and is an exclusionary criteria
in some studies [e.g., aerobic exercise therapy vs. cognitive
behavioral therapy (46)]. It is therefore not surprising that
motor predictors of treatment adherence are often reported.
For example, symptomatic orthopnoea and dyspnoea, nocturnal
hypoventilation, and spinal onset of symptoms have been
associated with adherence to non-invasive ventilation (47–50).
Functional scores (forced volume vital capacity and the revised
ALS Functional Rating Scale) have also been identified as
independent predictors of adherence to clinical trials and fewer
protocol deviations (51).
CAREGIVER BURDEN IN ALS
Several studies have shown that caregiving in ALS affects
caregivers’ level of distress and quality of life (52). The
psychological symptoms experienced by caregivers have a
significant impact on caregiver burden (53). Burke et al. (54)
demonstrated that caregiver distress explained 39% of the
variance in caregiver burden (54). In another study where
caregivers were dichotomized into low and high burden groups,
there were no differences across groups with respect to motor
function (revised ALS Functional Rating Scale), bulbar/spinal
onset, or survival time. Significant differences were only found
when high and low-burden caregivers were compared on
levels of anxiety, depression, distress and quality of life (55).
A longitudinal study involving ALS patients with relatively
preserved cognition demonstrated that anxiety and depression in
caregivers were the best long-term predictors of burden (56).
An interesting study using a mixed methods approach
(quantitative and qualitative) to assess burden in 81 informal
ALS caregivers, showed that increased psychological distress,
hours of care provided, and lower quality of life were the best
predictors of caregiver burden, explaining 53% of variance. These
caregivers identified difficulties related to four main themes:
(a) the caregiving role and tasks associated with management
of the condition, (b) psychosocial and emotional impact, (c)
limitated time and restricted social life, and (d) significant impact
in relationships with others and also identity (the process of
“becoming” and “being” a caregiver) (57). Longitudinal studies
have also demonstrated that disease severity causes strain and
burden in caregivers over time (58, 59).
THE IMPACT OF COGNITIVE AND
BEHAVIORAL SYMPTOMS ON CAREGIVER
BURDEN
Recent evidence has demonstrated that both cognitive and
behavioral symptoms contribute to caregiver burden in ALS
(54, 60). A study involving 33 ALS patient-caregiver dyads
showed that caregiver burden (Zarit Scale) was associated
with executive dysfunction and behavioral changes, such as
apathy and disinhibition (54). Similarly, findings from a
Chinese study revealed that the degree of frontal dysfunction
and behavioral changes (predominantly disinhibition) was
significantly associated with caregiver burden (60).
More severe cognitive deficits have also been shown to predict
caregiver burden in ALS (61). Conversely, a study involving
84 ALS patient-caregiver dyads found no correlation between
caregiver burden (Caregiver Burden Inventory) and cognitive
functioning (ALS-Cognitive Behavioral Screen). Only disease
progression and behavioral symptoms were correlated with
caregiver burden (62). Indeed, the level of burden for caregivers
of ALS-FTD patients appears to increase with disease progression
compared to a persistently high level of burden among caregivers
of FTD patients (63).
Few studies have found specific motor symptoms associated
with caregiver burden. One study linked poor motivation
and difficulties with everyday skills to higher burden (64),
while another study revealed that caregiver burden was
predicted by behavioral problems and severity of limb
involvement (65).
These findings highlight the support caregivers require from
health care professionals and family/friends to not only manage
the emotional and physical burden of caregiving (66), but also
cognitive and behavioral symptoms that can greatly impact on
their caregiving experience.
DISCUSSION
Assessment and management of cognitive and behavioral
symptoms forms the larger goal of preservation of quality of
life in both ALS patients and caregivers. Timely assessment of
cognitive and behavioral symptoms has important prognostic
and therapeutic implications. The presence of dysexecutive
symptoms is not only likely to impact on patient and caregiver
psychological well-being but also decision-making, adherence
to life-sustaining interventions, and capacity to engage and
benefit from non-pharmacological interventions. Additionally,
cognitive and behavioral symptoms may exist before full blown
motor symptoms (67) and, therefore, the ability to make
informed decisions may be effected early in the disease course.
While treatments for symptomatic management in ALS is
often most beneficial if initiated early [e.g., (68)] and clinicians
value proactive decisions (69), failure to identify cognitive and
behavioral symptoms may mean that patients are not fully
supported by their health care team and caregivers to undertake
informed decision-making that is in accordance with their
current personal philosophy and values (70).
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The provision of practical support by ALS specialists is known
to facilitate adherence in ALS. Increased educational training and
adaptation facilitates adherence to non-invasive ventilation (71);
telemonitoring decreases emergency room visits and hospital
admissions, and follow-up care between clinical visits increase
adherence to clinical recommendations (36, 72). Support from
other ALS patients through online platforms can also increase
treatment adherence such as with medication adherence (73).
It is also essential to recognize the importance of caregivers
in the management of ALS from an early stage, informing them
about the possibility of burden, offering themhealth care support,
and monitoring their well-being over time (74). Weisser et al.
(75) showed that the needs of ALS caregivers were multiple,
including practical, social, and psychological needs. A model of
coping was subsequently proposed integrating resilience, burden,
needs, and rewards (75). An intervention to reduce maladaptive
coping strategies has also been found to improve well-being in
caregivers of patients with ALS (76). Furthermore, the use of
technological approaches (e.g., telemedicine) for ALS patients
and their caregivers that live in remote and rural areas which have
reduced access to health care services may be especially beneficial
(77). Provision of training for health care professionals to help
patients and caregivers during the advanced stages of the disease
would also ensure that important factors such as fatigue, stress,
and ethical challenges related to end-of-life care are adequaly
addressed (78).
To the best of our knowledge, there are currently no evidence-
based studies which examine interventions to manage the
cognitive and behavioral symptoms of ALS patients, though there
are a few that examine caregiver burden in response to behavioral
symptoms (79). In the absence of such evidence, it is possible
to extrapolate findings from intervention studies in non-ALS
populations as possible non-pharmacological interventions for
cognitive and behavioral symptoms in ALS. Behavioral variant
FTD and cognitively impaired ALS show similar cognitive
profiles, although cognitive deficits are more severe in patients
with behavioral variant FTD in most domains (4). In both
disorders, considerable impairment in social cognition, fluency
and verbal memory is found, whereas impairment of visual
memory and attention is less prominent (3, 4). Due to the
similarity of symptoms, studies examining management of
behavioral variant FTD may be relevant to ALS, though caution
should be used in extrapolating their conclusions.
Environmental management has shown promise in addressing
cognitive/behavioral symptoms of FTD patients (80). For
example, reducing noise and stimulation, lessening clutter,
or simplifying social situations can help patient’s better
focus on a nominated task or response (80, 81). Removing
access to problematic stimuli or modifying public outings
to reduce the opportunity for inappropriate interactions are
also effective FTD-specific environmental manipulations (80,
81), which could also be implemented when working with
ALS patients presenting symptoms of disinhibition or loss of
social cognition.
Though the research on behavioral modification in FTD is
also limited and consists mainly of case studies and reports,
clinicians have typically focused on disinhibition, apathy
and compulsive behaviors (80, 82). In a few specific cases,
behavioral interventions successfully reduced behaviors that
were most distressing for patients’ and caregivers’, improved
the relationship between patients’ and caregivers’, and helped
to prevent the patients from being institutionalized (82, 83).
Two case reports used behavior theory techniques including
reducing stimuli, introducing new non-verbal cues, and
creating reward systems (82, 83). Similarly, Tailored Activities
Programs have been shown to reduce agitation in behavioral
variant FTD patients (83–85). Support groups for family
caregivers have also proved helpful (in person and when using
online live streams) and most effective when caregivers are
experiencing similar behaviors and challenges with the patient
(86, 87).
There are limitations to understanding the impact of
cognitive and behavioral changes on patients with ALS and
their caregivers. The majority of published studies have been
completed in developed countries and thus results cannot be
extrapolated to all countries. Also, many of these studies do
not take into consideration the various socioeconomic variables
attributable to the patient and caregivers daily experience with
ALS, such as the individual’s wealth or their country’s health
care system.
Despite the clinical necessity of an intervention to manage
cognitive and behavioral symptoms, there has been a lack of
research on the topic which further widens the gap between
research and practice. Drawing from interventions in dementia,
there is a large landscape of possible, untested interventions
for cognitive and behavioral symptoms of ALS. Early and
comprehensive management of cognitive and behavioral
symptoms not only promotes holistic care of patients but
would also further enhance caregiver’s psychological well-
being and likely to reduce the healthcare and societal burden
of these symptoms due to poor intervention adherence and
avoidable hospitalizations.
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